Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a development stage enterprise, covers the month of September 2024. The report was signed on September 20, 2024, by Geoffrey P. Kempler, Chairman.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material change disclosed is a Change of Director's Interest Notice, submitted as Exhibit 99.1. No other material changes to operations or financial status are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves primarily to incorporate the Director's Interest Notice into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific details of the Director's Interest change referenced in Exhibit 99.1.
- Confirm the impact of this change on the company's governance structure.
- Review the referenced Registration Statements (S-8 and F-3) for broader context on capital raising activities.